News | Oblita

Development of a new leishmaniasis drug wins EU funding

TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of Neglected Infectious Diseases (NID) and their social and economic impacts. Funding from Horizon 2020,...

TT4CL is moving forward the R&D of a new molecule, D121, for cutaneous leishmaniasis by some more preclinical research as well as a phase 1 study

The beginnings of Oblita Therapeutic’s molecule D121

Preclinical research demonstrates D121 outcompetes miltefosine

Iran suffers from a high incidence of cutaneous leishmaniasis (CL)

The Statistician’s Role in Drug Development

BREAKING NEWS: A potential new oral drug for leishmaniasis hassuccessfully been tested in healthy humans

News from Oblita and TT4CL partners

Development of a new leishmaniasis drug wins EU funding

TT4CL is moving forward the R&D of a new molecule, D121, for cutaneous leishmaniasis by some more preclinical research as well as a phase 1 study

The beginnings of Oblita Therapeutic’s molecule D121

Preclinical research demonstrates D121 outcompetes miltefosine

Iran suffers from a high incidence of cutaneous leishmaniasis (CL)

The Statistician’s Role in Drug Development

BREAKING NEWS: A potential new oral drug for leishmaniasis hassuccessfully been tested in healthy humans